Compounds > methylene-dehydroacetoxy-progesterone
Page last updated: 2024-11-08

methylene-dehydroacetoxy-progesterone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methylene-dehydroacetoxy-progesterone: RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID188952
CHEMBL ID3276159
SCHEMBL ID3934288
MeSH IDM0054986

Synonyms (20)

Synonym
methylene-dehydroacetoxy-progesterone
805-84-5
[(8r,9s,10r,13s,14s,17r)-17-acetyl-10,13-dimethyl-16-methylidene-3-oxo-1,2,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-yl] acetate
17-hydroxy-16-methylene-delta 6-progesterone-17-acetate
kur23m82tz ,
unii-kur23m82tz
superlutin
methenmadinone acetate
17-hydroxy-16-methylene-delta6-progesterone 17-acetate
CHEMBL3276159
SCHEMBL3934288
16-methylene-6-dehydro-17.alpha.-acetoxyprogesterone
mdap
17-hydroxy-16-methylene-.delta.6-progesterone-17-acetate [mi]
17-hydroxy-16-methylene-.delta.6-progesterone-17-acetate
17.alpha.-acetoxy-16-methylenepregna-4,6-diene-3,20-dione
17alpha-acetoxy-16-methylene-4,6-pregnadiene-3,20-dione
Q27282450
17-(acetyloxy)-16-methylenepregna-4,6-diene-3,20-dione
DTXSID701001282
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1150490Progestational activity in immature rabbit assessed as proliferation of uterus administered intramuscularly by haematoxylin and eosin staining-based assay1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Quantitative structure-activity relationships among steroids. Investigations of the use of steric parameters.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (20.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (20.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ethinyl estradiol
Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.		1.961017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
mestranol
[no description available]		1.971017beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound		prodrug;
xenoestrogen
chlorsuperlutin
chlorsuperlutin: RN given refers to cpd without isomeric designation; structure		1.9510
melengestrol acetate
Melengestrol Acetate: A 6-methyl PROGESTERONE acetate with reported glucocorticoid activity and effect on ESTRUS.		1.9510corticosteroid hormone
ConditionIndicatedRelationship StrengthStudiesTrials
Convulsions, Grand Mal
[description not available]		01.9610
Epilepsy, Tonic-Clonic
A generalized seizure disorder characterized by recurrent major motor seizures. The initial brief tonic phase is marked by trunk flexion followed by diffuse extension of the trunk and extremities. The clonic phase features rhythmic flexor contractions of the trunk and limbs, pupillary dilation, elevations of blood pressure and pulse, urinary incontinence, and tongue biting. This is followed by a profound state of depressed consciousness (post-ictal state) which gradually improves over minutes to hours. The disorder may be cryptogenic, familial, or symptomatic (caused by an identified disease process). (From Adams et al., Principles of Neurology, 6th ed, p329)		01.9610
Gigantism
The condition of accelerated and excessive GROWTH in children or adolescents who are exposed to excess HUMAN GROWTH HORMONE before the closure of EPIPHYSES. It is usually caused by somatotroph hyperplasia or a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. These patients are of abnormally tall stature, more than 3 standard deviations above normal mean height for age.		01.9610
Postpartum Amenorrhea
[description not available]		01.9710
Amenorrhea
Absence of menstruation.		01.9710
Anorexia Nervosa
An eating disorder that is characterized by the lack or loss of APPETITE, known as ANOREXIA. Other features include excess fear of becoming OVERWEIGHT; BODY IMAGE disturbance; significant WEIGHT LOSS; refusal to maintain minimal normal weight; and AMENORRHEA. This disorder occurs most frequently in adolescent females. (APA, Thesaurus of Psychological Index Terms, 1994)		01.9710